Investors Launch Class Action Suit Against Zoetis Over Product Claims
Investors who purchased Zoetis Inc. stock between January 14, 2025, and May 6, 2026, face a July 27 deadline to join a class action lawsuit. The litigation alleges the pharmaceutical company misled shareholders regarding the performance and safety of its key veterinary products, including Librela, Apoquel, and Cytopoint.




















